Evaxion Biotech A/S Q3 2024 Earnings Report

Evaxion Biotech A/S EPS Results

• Actual EPS: -$0.20
• Consensus EPS: -$0.60
• Beat/Miss: Beat by +$0.40
• One Year Ago EPS: N/A

Evaxion Biotech A/S Revenue Results

• Actual Revenue: $3.02 million
• Expected Revenue: $0.19 million
• Beat/Miss: Beat by +$2.83 million
• YoY Revenue Growth: N/A

Evaxion Biotech A/S Announcement Details

• Quarter: Q3 2024
• Date: 10/31/2024
• Time: N/A

Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.